Table of Contents
Patients’ Relapses Raise New Questions
James, a 55-year-old engineer diagnosed with lung cancer, initially relied on his immune system to combat the disease alongside conventional treatments.
Although the initial therapeutic response appeared promising, the cancer quickly progressed within a few months. “It felt like my body was double-crossing me,” he said.
Experiences like James’s not only demonstrate the profound personal impact of unexpected disease progression, but also underscore a central scientific challenge: understanding how cancer so effectively evades or manipulates the body’s natural immune defenses, a question whose resolution could significantly improve treatment strategies and patient outcomes broadly.
Maria, a 42-year-old mother of two, had a similar experience. After chemotherapy, her scans showed she was in remission. Less than a year later, the cancer came back, this time more aggressive.
Doctors questioned why her immune system did not protect her. These unresolved clinical observations, where patients experience relapse despite an initially successful treatment, have directly motivated researchers to investigate the biological processes—such as immune evasion—that might explain such outcomes.
Scientists Discover Immune Betrayal
Researchers at the University of Geneva, together with the Ludwig Institute for Cancer Research, think they have found an answer. Their study shows that tumours do more than just hide from the immune system; they actually change how it works.
Neutrophils are the most common immune cells in the body and are usually the first to respond to infections. However, when neutrophils are present within tumours, they undergo reprogramming that alters their normal function.
Instead of identifying and attacking cancer cells, these reprogrammed neutrophils begin to produce a molecule called CCL3.
This chemokine not only supports tumour growth by fostering a microenvironment favorable to cancer cell survival, but also promotes inflammation that can facilitate tumour progression and spread.
“This is a betrayal from within,” said Professor Mikaël Pittet, who led the study. “Neutrophils recruited by the tumour undergo a reprogramming of their activity. They begin producing CCL3 locally, which promotes tumour growth.”
Technical Breakthrough in Cancer Research
Studying neutrophils is notoriously difficult because they are difficult to genetically manipulate. Co‑author Evangelia Bolli recalls the painstaking process: “We combined different approaches to control the expression of the CCL3 gene specifically in neutrophils, without inhibiting it in other cells. A delicate exercise!”
When CCL3 was removed, neutrophils no longer supported tumour growth, even though they continued to function normally elsewhere in the body. This breakthrough confirmed that CCL3 is a key driver of cancer progression.
To confirm their results, bioinformatics expert Pratyaksha Wirapati analysed large datasets from other cancer studies. Using new analytical tools, the team found that neutrophils frequently produced high levels of CCL3 across many cancer types. This means that neutrophils, a type of white blood cell normally involved in defending the body against infections, were consistently making more of the CCL3 signaling molecule in tumor environments. Globally, this widespread pattern suggests that targeting CCL3 could have broad therapeutic value for improving cancer outcomes across diverse populations.
In local contexts such as Nigeria, where cancer rates are rising and diagnostic resources are limited, identifying CCL3 as a measurable biomarker may help with earlier detection of aggressive cancers and inform the development of tailored treatment strategies.
This evidence highlights CCL3’s potential as both a biological indicator for aggressive cancer and a promising target for interventions with global and local relevance.
Why This Matters for Nigeria
Cancer cases are rising in Nigeria, with breast and prostate cancers among the most common. This surge not only places a significant burden on the country’s healthcare infrastructure but also has far-reaching societal implications, as it exacerbates economic pressures on families and constrains access to effective care for many individuals.
The strain on healthcare resources highlights the urgent need for more effective and accessible treatment strategies that can be adapted to local realities.
Doctors emphasise that scientific discoveries such as the identification of immune system manipulation could inform the development of locally relevant, more personalised therapies, a crucial consideration given the limited resources available in many communities.
Furthermore, improving understanding of how cancer subverts immune responses may enable earlier intervention and better disease management for Nigerian patients. Such advancements could reduce the frequency of relapses, mitigate treatment-associated financial hardships, and ultimately contribute to improved public health outcomes at both the individual and societal levels.
Health advocates emphasise that, despite promising research, early detection is important. “We need more investment in cancer research and awareness,” said one Lagos oncologist. “Understanding how the immune system is manipulated could inform future treatments in Nigeria.”
Gazing Forward: Hope for Future Therapies
The Geneva study suggests that blocking or neutralising CCL3 could prevent immune cells from supporting cancer, thereby enabling the immune system to better protect the body. Researchers hope that drugs targeting CCL3, particularly when combined with existing immunotherapies, could improve treatment outcomes.
Such advancements may result in fewer relapses, slower disease progression, and more personalised therapeutic strategies for patients.
Beyond individual patient benefits, these findings carry important societal implications by informing the development of future therapies and public health approaches, particularly in populations facing increasing cancer rates and limited healthcare resources.
Published in Cancer Cell, the study highlights not only the complexity of cancer’s evasion of immune surveillance but also demonstrates how ongoing scientific research can contribute to improved health outcomes at both individual and societal levels.
What Is CCL3?
- CCL3 is a chemokine—a signalling molecule that guides immune cells.
- Normally, it helps coordinate immune responses to infection.
- Inside tumours, neutrophils begin producing excess CCL3.
- Instead of fighting disease, this excess CCL3 promotes tumour growth and spread.
- Scientists now see CCL3 as a potential biomarker for aggressive cancer progression and a possible target for new therapies.
